Growing European Drug Developer Awards $1.5 Million Study to eResearchTechnology
Commitment Continues Global Trend Toward Thorough Phase I ECG Studies
eResearchTechnology, Inc. (eRT) announced that it has been awarded a Thorough Phase I ECG Study valued at more than $1.5 million in cardiac safety monitoring and services from a growing European drug developer for one of its compounds in clinical trials.
The award covers a significant Thorough Phase I ECG Study, for which eRT is providing comprehensive support, including provision of digital 12-lead ECG equipment designed to facilitate collection of cardiac safety data that is subsequently provided to eRT for analysis. eRT will perform digital collection, measurement, interpretation, review, and distribution of cardiac safety data through its EXPeRT(R) workflow enabled data handling technology, the first solution in production that was designed explicitly to meet emerging international regulatory guidance and technical standards.
"eRT has worked closely with this sponsor in providing cardiac safety services throughout the clinical development of this compound and is delighted at being able to extend collaboration to this critical Thorough Phase I ECG Study," said Scott Grisanti, senior vice president of business development and chief marketing officer at eRT. "In addition, this award illustrates the continued trend toward global implementation of maturing regulatory guidance and international standards."
Other news from the department science
